US20220061310A1 - Method for stabilizing bioactivity of growth factor - Google Patents
Method for stabilizing bioactivity of growth factor Download PDFInfo
- Publication number
- US20220061310A1 US20220061310A1 US17/418,305 US201917418305A US2022061310A1 US 20220061310 A1 US20220061310 A1 US 20220061310A1 US 201917418305 A US201917418305 A US 201917418305A US 2022061310 A1 US2022061310 A1 US 2022061310A1
- Authority
- US
- United States
- Prior art keywords
- growth factor
- factor
- bioactivity
- concentration
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003102 growth factor Substances 0.000 title claims abstract description 136
- 238000000034 method Methods 0.000 title claims abstract description 30
- 230000000087 stabilizing effect Effects 0.000 title abstract description 4
- 108010035532 Collagen Proteins 0.000 claims abstract description 60
- 102000008186 Collagen Human genes 0.000 claims abstract description 60
- 229920001436 collagen Polymers 0.000 claims abstract description 60
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 48
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 29
- 239000011159 matrix material Substances 0.000 claims description 25
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 18
- 102000013275 Somatomedins Human genes 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 10
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 10
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 10
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 10
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims description 10
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims description 10
- 102000003951 Erythropoietin Human genes 0.000 claims description 10
- 108090000394 Erythropoietin Proteins 0.000 claims description 10
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 10
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 10
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 10
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 10
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 10
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 10
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 10
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 10
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 10
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 10
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 10
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 10
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 10
- 229940105423 erythropoietin Drugs 0.000 claims description 10
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 10
- 229940053128 nerve growth factor Drugs 0.000 claims description 10
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 10
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229940099552 hyaluronan Drugs 0.000 claims description 7
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 7
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 5
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 5
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 5
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 5
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 5
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 5
- 101000653787 Mus musculus Protein S100-A11 Proteins 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 5
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- 210000000440 neutrophil Anatomy 0.000 claims description 5
- 229940076279 serotonin Drugs 0.000 claims description 5
- 210000000130 stem cell Anatomy 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 5
- 102100036537 von Willebrand factor Human genes 0.000 claims description 5
- 229960001134 von willebrand factor Drugs 0.000 claims description 5
- 230000017423 tissue regeneration Effects 0.000 claims description 4
- 229920002971 Heparan sulfate Polymers 0.000 claims description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002567 Chondroitin Polymers 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 238000012792 lyophilization process Methods 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 1
- 108091016585 CD44 antigen Proteins 0.000 claims 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 claims 1
- 108090000054 Syndecan-2 Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 abstract description 11
- 238000002156 mixing Methods 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 108010081589 Becaplermin Proteins 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229940116157 regranex Drugs 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 3
- 108010084455 Zeocin Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- -1 tenacin Proteins 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/362—Skin, e.g. dermal papillae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/48—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
Definitions
- This invention discloses a method for stabilizing bioactivity of a growth factor, and a composition with bioactivity of growth factor preserved and prepared by the method.
- Growth factors comprise a group of proteins responsible for signal transduction inside or between cells, and regulation of cell growth, differentiation, and other functions by binding to specific cell surface receptors.
- PDGF platelet-derived growth factor
- EGF epidermal growth factor
- KGF keratinocyte growth factor
- TGF- ⁇ transforming growth factor
- FGF fibroblast growth factor
- SCF stem cell factor
- IGF-I insulin-like growth factors
- NGF nerve growth factor
- BMP bone morphogenetic protein
- CTGF connective tissue growth factor
- VEGF vascular endothelial growth factor
- CSF colony stimulating factor
- BDNF brain-derived neurotrophic factor
- BDNF brain-derived neurotrophic factor
- EPO endothelial cell monocytes active polypeptide
- endothelial-monocyte activating polypeptide epithelial neutrophil activating peptide
- GDNF glial derived neurotrophic factor
- GCSF granulocyte colony-stimulating factor
- GM granulocyte macrophage colony-stimulating factor
- the rhPDGF in Regranex® Gel is genetically engineered by mutating, deleting, or replacing a naturally occurring PDGF sequence, and then placed in plasmids to produce a recombinant protein, so its bioactivity can be stabilized at room temperature.
- Regranex® Gel is very expensive, inconvenient to use, requiring low-temperature storage, its annual output value is as high as US S270 million, showing that its market demand is quite huge.
- the FDA officially announced that Regranex® Gel may increase the risk of cancer and the risk of death by up to 5 times after more than 10 years of follow-up study. This demonstrates that growth factors containing non-naturally occurring sequences, especially having prolong life-selves may be risk and may not be suitable for clinical treatment.
- native growth factors have short half-lives and their bioactivities are rapidly degraded at room temperature, thus limiting the application of native growth factors in clinical treatment.
- the current application proposes a natural way of drying the mixture of collagen and growth factors, and the bioactivity of growth factors can be preserved at room temperature for at least 7 days. Furthermore, the bioactivity of growth factors can be preserved with collagen containing extracellular mixtures under a dry state at room temperature. And the bioactivity of growth factors can be resumed in a wet condition.
- the present invention discloses a method for stabilizing a bioactivity of a growth factor, including: providing a native growth factor; adding a matrix molecule (e.g., a collagen, a collagen derivative, a gelatin, a hyaluronan, or a combination thereof) to the native growth factor; and performing a drying step to obtain a composition with the bioactivity of growth factor preserved.
- a matrix molecule e.g., a collagen, a collagen derivative, a gelatin, a hyaluronan, or a combination thereof.
- composition After the composition is at room temperature for 7 days or more (e.g., 7 to 20 days, 1-6 months, or 12 months or more), 70% ⁇ 30% (e.g., 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%) of the bioactivity, as compared to the bioactivity at day 0, can be preserved.
- 70% ⁇ 30% e.g., 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%
- native growth factor refers to a growth factor that naturally exists in animal, especially in human, and its amino acid sequence has not been changed by mutations such as insertions, deletions, or replacements.
- the native growth factor is one that exhibits its native activities, e.g., binding to its receptor and mediating downstream events.
- the native growth factor is selected from, but not limited to: platelet-derived growth factor (PDGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), transforming growth factor (TGF- ⁇ , TGF- ⁇ ), fibroblast growth factor (FGF), stem cell factor (SCF), insulin-like growth factors (IGF-I, IGF-II), nerve growth factor (NGF), bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), colony-stimulating factor (CSF, M-CSF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor, erythropoietin (EPO), endothelial cell monocytes active polypeptide (endothelial-monocyte activating polypeptide), epithelial neutrophil activating peptide, glial derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (GCSF), granulocyte macrophage colon
- the drying step is performed by a freeze-drying or lyophilization method.
- the concentration of the matrix molecule is 1 to 100 mg/ml (e.g., 3 to 60 mg/ml, 3 mg/ml, 9, mg/ml, 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, or 100 mg/ml), and the concentration of the growth factor is 1 ng/ml to 1 ⁇ g/ml (e.g., 10 to 900 ng/ml, 30 to 900 ng/ml, 100 to 500 ng/ml, 30 ng/ml, 60 ng/ml, 90 ng/ml, 120 ng/ml, 150 ng/ml, 180 ng/ml, 360 ng/ml, or 900 ng/ml).
- the concentration of the growth factor is 1 ng/ml to 1 ⁇ g/ml (e.g., 10 to 900 ng/m
- the concentration ratio of the native growth factor to the matrix molecule can be 1 ⁇ 10 ⁇ 9 to 1:1 (e.g., 1 ⁇ 10 ⁇ 3 to 1 ⁇ 10 ⁇ 6 :1, or 1.67 ⁇ 10 ⁇ 8 to 3.33 ⁇ 10 ⁇ 4 :1).
- the composition of growth factor may be further stored between ⁇ 80° C. to 37° C.
- the present invention further discloses a growth factor composition in which the bioactivity of the growth factor composition can be preserved for at least seven days at room temperature.
- the composition is prepared by the preparation method provided by the present invention.
- the composition includes: a growth factor; and a matrix material.
- the concentration ratio of the growth factor to the matrix material is 1 ⁇ 10 ⁇ 3 to 1 ⁇ 10 ⁇ 6 :1.
- the matrix molecule is collagen. In a preferred embodiment, the concentration of the collagen is 3-60 mg/ml.
- the growth factor is selected from the group consisting of, but not limited to: platelet-derived growth factor (PDGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), transforming growth factor (TGF- ⁇ , TGF- ⁇ ), fibroblast growth factor (FGF), stem cell factor (SCF), insulin-like growth factors (IGF-I, IGF-II), nerve growth factor (NGF), bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), colony stimulating factor (CSF, M-CSF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor, erythropoietin (EPO), endothelial cell monocytes active polypeptide (endothelial-monocyte activating polypeptide), epithelial neutrophil activating peptide, glial derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (GCSF),
- PDGF platelet
- the growth factor composition can be further stored at ⁇ 80° C. ⁇ 37° C.
- FIG. 3 shows the bioactivity measurement results of storing a growth factor PDGF solution at various time points at room temperature.
- FIG. 4 shows the bioactivity measurement results of a growth factor PDGF at the indicated concentrations combined with 9 mg/mL of collagen without lyophilization in comparison with a fresh PDGF solution at 6 hours.
- FIG. 5 shows the bioactivity measurement results of a growth factor PDGF at indicated various concentrations combined with 3 mg/mL of collagen and lyophilized in comparison to the bioactivity of the corresponding PDGF solution measured at 6 hours in room temperature.
- FIG. 6 shows the bioactivity measurement results of growth factor PDGF obtained by different preparation methods. Three concentrations of PDGF were lyophilized with collagen or alone without collagen, and together with respective aqueous PDGF solutions, were stored at room temperature for 0, 1, 2, 3, 7 days prior to bioactivity assay.
- FIG. 7 shows the bioactivity measurement results of various growth factors as indicated. The amounts of growth factors and collagen and their preservation condition prior to experiments are as indicated.
- FIG. 8 shows the bioactivity measurement results of various growth factors as indicated. The amounts of growth factors and collagen and their preservation condition prior to experiments are as indicated.
- bioactivity of a native growth factor can be stabilized at room temperature by mixing the growth factor with a matrix molecule and subjecting the mixture to a drying or lyophilization process.
- a matrix molecule can be an extracellular molecule found in the extracellular matrix. Examples are, but are not limited to, collagen, hyaluronan, gelatin, fibronectin, elastin, tenacin, laminin, vitronectin, aggrecan, polypeptides, heparan sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, dermatan sulfate, carrageenan, heparin, chitin, chitosan, alginate, agarose, agar, cellulose, methyl cellulose, carboxyl methyl cellulose, glycogen and derivatives thereof.
- the matrix molecule can be fibrin, fibrinogen, thrombin, and polyglutamic acid, a synthetic polymer (e.g., acrylate, polylactic acid, polyglycolic acid, or poly(lactic-co-glycolic acid), silk fibroin, polylysine, polyamino acids.
- a synthetic polymer e.g., acrylate, polylactic acid, polyglycolic acid, or poly(lactic-co-glycolic acid
- silk fibroin fibroin
- polylysine polyamino acids
- Collagen can be easily isolated and purified from collagen-rich tissues such as skin, tendon, ligament, and bone of humans and animals. Methods for isolating and purifying collagen are well known in the art. (See, e.g., U.S. Pat. No. 5,512,291; US Patent Publication 20040138695; Methods in Enzymology, vol. 82, pp. 33-64, 1982; The Preparation of Highly Purified Insoluble Collagen, Oneson, I., et al., Am. Leather Chemists Assoc., Vol. LXV, pp.
- Collagen can also be prepared by recombinant technology, such as those described by Advanced Tissue Sciences (La Jolla, Calif.) or purchased from various venders (e.g., Fibrogen; South San Francisco, Calif.).
- An aqueous solution containing the growth factor and the matrix molecules, and one or more other optional materials can be prepared in a buffered solution having a pH of 2-10 (e.g., a pH of 5 to 8).
- a buffered solution having a pH of 2-10 e.g., a pH of 5 to 8.
- Low ion solutions such as saline containing 0.135 M NaCl can be used.
- the solution is subjected to a drying process to remove water from the solution.
- Any suitable drying process known in the art can be used, e.g., freeze-drying, lyophilization, and vacuum drying.
- the addition of other components can still maintain the bioactivity of the growth factor.
- Preserving the composition in a dry state is also key to maintaining the bioactivity of the growth factor.
- Example 1 Construction of Recombinant Human PDGF B (rhPDGF B) Expression Vectors and Purification of rhPDGF B
- the linear DNA fragments encoding native hPDGF B was obtained from pCMV-SPORT6 (Invitrogen, Grand Island, N.Y. USA) by PCR performed with a sense primer (5′-GGA TTC AGC CTG GGT TCC CTG ACC ATT-3′; SEQ ID NO: 1) and anti-sense primers (5′-GCA GCT GCA CGG CCT GTG ACC TGA-3′; SEQ ID NO: 2) in which the EcoR I sites were introduced.
- rhPDGF B cDNA fragment was double digested with EcoR I (TaKaRa, Japan), purified by agarose gel electrophoresis, and cloned into pPICZ ⁇ A to yield pPICZ ⁇ A/rhPDGF B.
- EcoR I EcoR I
- cloned into pPICZ ⁇ A to yield pPICZ ⁇ A/rhPDGF B.
- the procedures for small scale preparation of plasmid, digestion with restriction enzymes, ligation, and transformation all followed the standard methods.
- PCR was carried out using 2.5 U of Taq DNA polymerase (TaKaRa) in a final volume of 50 ⁇ L using the following conditions: 95° C. for 10 min, 30 cycles (95° C. for 60 s, 55° C. for 30 s, and 72° C. for 60 s) and a final extension at 72° C. for 7 min.
- the plasmids pPICZ ⁇ A/rhPDGF B was linearized with Sac I and transformed into yeast Pichia pastoris strain X33 using the electroporation method according to the supplier's instruction. Transformed cells were then plated onto YPDS containing 100 ⁇ g/mL zeocin and incubated at 30° C. for at least 3 days. Single colonies were transferred simultaneously onto Minimal Methanol Medium (MM) and Minimal Dextrose Medium (MD) plates to test their methanol utilization phenotype. The MM and MD plates were incubated at 30° C. for 2 days to distinguish between the Mut s and Mut + recombinants. Recombinant strains containing the rhPDGF B gene were screened by colony PCR. Several clones with the Mut + phenotype that expressed the maximal levels of rhPDGF B was chosen in small-scale expression and stored in YPD containing 15% glycerol for further scale-up cultures.
- zeocin-resistant transformants Selected colonies of zeocin-resistant transformants were inoculated into 5 mL of Yeast Extract-Pepttone-Dextrose (YPD) broth (1% yeast extract, 2% peptone, 2% glucose) containing 100 ⁇ g/mL zeocin at 30° C., grown to stationary phase, and used to inoculate 300 mL of Buffered Glycerol-complex Medium (BMGY). After incubation at 30° C. with shaking at 100 rpm, the cells were centrifuged at 3,000 ⁇ g for 10 min and the pellets resuspended in 1000 mL of Buffered Methanol-Complex Medium (BMMY) to OD 600 of 1.
- YPD Yeast Extract-Pepttone-Dextrose
- BMGY Buffered Glycerol-complex Medium
- the cells were allowed to grow for 72 h at 30° C., and methanol was added every 24 h to a final concentration of 0.5 ⁇ 1% (v/v) to induce expression of the target protein. After 72 h, cells were removed by centrifugation at 3,000 ⁇ g for 5 min, and the supernatants were collected. For recombinant protein detection, the supernatants were analyzed by 15% (w/v) SDS-PAGE.
- the construct contained the yeast ⁇ -factor promoter, which directs the secretion of rhPDGF B, followed immediately by the sequence for mature rhPDGF B beginning with the glutamate at amino acid position 1.
- Culture supernatants were applied to a phenyl column (GE Healthcare, Piscataway, N.J. USA) pre-equilibrated with buffer (0.01 M sodium phosphate, 1.5 M ammonium sulfate; pH 6). After loading, the column was washed with the same buffer and eluted with a linear gradient of 1.5 ⁇ 0 M ammonium sulfate in the same buffer. The active fractions (5 mL) were collected using a flow rate of 60 mL/h. After centrifugation at 20,000 ⁇ g for 30 min at 4° C., each sample was loaded onto a CM-Sepharose (GE Healthcare, Piscataway, N.J.
- rhPDGF B was used to detect rhPDGF B with 6-His tag overexpressed from culture supernatant derived from Pichia transformants carry rhPDGF B-6His tag.
- the amount of purified rhPDGF B was determined by BCA protein analysis using bovine serum albumin (BSA) as a standard.
- BSA bovine serum albumin
- the 293-SL/PR cell line was a transformed cell line expressing a PDGF receptor PDGFR ⁇ on the surface of a 293T cell line.
- the 293-SL/PR cells were seeded at 1 ⁇ 10 4 cells/cm 2 in cultural wells. After cell attachment in DMEM-10% FBS for 20 hours, serum starvation was performed for 16 hours, then different concentrations of PDGF in DMEM-2% FBS were added and cultured at 37° C. in an incubator with 5% CO 2 . At various time points, cells were lysed with 1 ⁇ Cell Culture Lysis Buffer (Promega) at room temperature with shaking for 15 min, then were centrifuged at 13,680 ⁇ g for 10 min at 4° C. Luciferase analysis reagent (100 ⁇ L; Promega) was added to 20 ⁇ L of the supernatant and bioluminescence was measured in a luminometer (Berthold).
- the bioactivity of the growth factor PDGF prepared as described above was measured by luciferase assay (day 0), and then stored at ⁇ 80° C. for seven months. After that, its bioactivity was measured again. The results showed that there were no significant differences in the bioactivity of the growth factor PDGF at different concentrations (0 ng/mL, 18 ng/mL, and 180 ng/mL) at day 0 and seven months later.
- the bioactivity of the growth factor PDGF prepared in above was measured under repeated freezing ( ⁇ 80° C.) and thawing (0° C.) mode. As shown in FIG. 2 , repeated freezing-thawing did not reduce bioactivity of the growth factor PDGF.
- the bioactivity of a PDGF solution was very stable under storage temperature of ⁇ 80° C. and was not susceptible to repeated freeze-thaw cycles, its stability above room temperature was examined.
- the PDGF prepared as above in Example 1 was dissolved in DMEM and diluted to 180 ng/mL, and incubated at 37° C. for 0, 2, 4, 6, 12, 24, 36, and 48 hours, respectively.
- the bioactivity of PDGF was measured with a commercially available Human PDGF FlowCytomix Simplex Kit (Invitrogen) and flow cytometry was used to measure bioactivity.
- the results in FIG. 3 showed that the PDGF was very unstable at 37° C.
- the PDGF prepared was dissolved in DMEM and diluted to 180 ng/mL, then mixed with 9 mg/mL of collagen. After incubation at 37° C. for 6 hours, the bioactivity was measured, as shown in FIG. 4 .
- the results showed that, at the same concentration (180 ng/mL), the growth factor without added collagen had higher bioactivity. Even if 9 mg/mL of collagen was added to the growth factor solutions at concentrations 900 ng/mL, 1800 ng/mL, and 9000 ng/mL, respectively (see Table 1), the bioactivity did not increase relatively with the growth factor concentration.
- the native growth factor prepared in Example 1 was combined with collagen and then lyophilized 100 ⁇ L of solutions each containing 3 mg/mL of collagen and different concentrations of the growth factor (0, 30, 60, 90, 120, 150, 180, 360 or 900 ng/mL) were prepared. See Table 2.
- the collagen-growth factor solutions were frozen at ⁇ 80° C. for 8 hours, and then lyophilized by a freeze dryer. The conditions of the freeze dryer are shown in Table 3.
- the results in FIG. 5 showed that the control group, PDGF solution, exhibited the highest bioactivity at 120 ng/mL (3.4 ⁇ 10 5 RLU/sec). However, as the growth factor concentration increased, the bioactivity decreased relatively, showing the occurrence of inhibition.
- the growth factor had a bioactivity of 3.1 ⁇ 10 5 RLU/sec at a concentration of 30 ng/mL, and its bioactivity increased relatively as the concentration of the growth factor increased.
- the bioactivities of the growth factor at various concentrations lyophilized with collagen were higher than the bioactivities of its corresponding growth factor solution. The results indicate the bioactivity was preserved by lyophilized collagen.
- the samples were used to treat 293-SL/PR cells for 30 min and their luciferase activity measured.
- the lyophilized powder group showed baseline luciferase activity
- the PDGF solution showed initial luciferase activity before day 1
- the lyophilized with collagen group showed persistent luciferase activity throughout 6 months of examination (data not all shown). See FIG. 6 .
- the PDGF in the aqueous solution group at 60 ng/mL and 180 ng/mL showed bioactivity at day 0. However, the bioactivity decreased rapidly thereafter. After one day of incubation, the bioactivity of the aqueous solution group was the same as the lyophilized powder group. Compared with the 60 ng/mL PDGF solution group, the bioactivity of the 60 ng/mL lyophilized with collagen combination group was higher, and even slightly increased after 1 day of incubation; the bioactivity was maintained for 6 months (data not shown). The same phenomenon was observed in the 180 ng/mL of PDGF lyophilized with collagen combination group.
- Some growth factors were purchased from commercial resources. In some cases, the native human growth factor gene was purchased from Addgene Headquarters, USA or other resources. The expression vector of the growth factor gene was constructed and screened. It was then overexpressed in a yeast expression system or other suitable expression systems such as CHO cell system and insect system. The expressed growth factor protein was then harvested and purified. Once purified, the growth factor protein was aliquoted and stored at ⁇ 80° C. to preserve its activity for use.
- the native growth factor prepared as above was frozen at ⁇ 80° C. and then lyophilized.
- the lyophilization procedure involved removing ice from the growth factor by sublimation under vacuum condition or under very low pressure.
- For mixing with collagen two procedures were taken: (1) Both collagen and growth factor in solutions were mixed initially and followed by a drying step to evaporate water gas under a low atmospheric pressure or a freeze-drying procedure using a lyophilizer; and (2) Collagen was dried initially and immersed in or sprayed with a growth factor solution, followed by a drying step as described above.
- NIH3T3 cells were seeded at 1.2 ⁇ 10 4 cells/cm 2 in a 48-well cultural plate. After cell attachment in DMEM-10% FBS for 24 hours, different concentrations as well as various growth factors in DMEM-1% FBS were cultured at 37° C. in an incubator with 5% CO 2 . After being cultured for another 3 days, the cells were lysed with sterilized water and DNA was released by freeze-thaw cycles between ⁇ 80° C. and room temperature. After transferring DNA samples to black fluorescence detection plate, 2 ⁇ g/ml of Hoechst 33258 in 1 ⁇ TNE buffer was added to each well and the fluorescence intensity was detected under excitation at 365 nm and emission at 460 nm. The cell numbers were calculated from cell number standards, which were confirmed by the above DNA detection and cell counting.
- FIGS. 7 and 8 Since bioactivities of growth factors in FIGS. 7 and 8 were measured by cell proliferation performance as described above, the efficacy of growth factor on cell proliferation corresponded well to its bioactivity throughout the assay period of 3 days.
- There were 6 experimental groups and 6 result bars for each growth factor studied are shown in FIGS. 7 and 8 : (1) freshly prepared growth factor solution, (2) growth factor pre-mixed with 10 mg/mL collagen before lyophilization and stored at ⁇ 80° C.
- growth factor pre-mixed with 60 mg/mL collagen before lyophilization and stored at ⁇ 80° C. before use (3) growth factor pre-mixed with 60 mg/mL collagen before lyophilization and stored at ⁇ 80° C. before use, (4) growth factor added to dried collagen at 60 mg/mL, lyophilized and stored at ⁇ 80° C. before use, (5) same as (3) but stored at room temperature for 1 week before use, (6) same as (4) but stored at room temperature for 1 week before use.
- FIGS. 7 and 8 demonstrated that bioactivities of growth factors, aFGF, bFGF, VEGF165, VEGF121, PDGF, and EGF, in aqueous solutions were indeed lower than the bioactivities of corresponding growth factor in combination with collagen. Although the bioactivities varied for different growth factors, higher amount of collagen preserved the bioactivities of growth factors. Compare the second bar with the 3 rd to 6 th bars in both FIGS. 7 and 8 . The storage temperature of the dried mixture of growth factor and collagen showed no significant impact on the bioactivities of the growth factors. Compare the 3 rd and 4 th bars ( ⁇ 80° C. storage) with the corresponding 5 th and 6 th bars (room temperature storage) in both FIGS. 7 and 8 . The results indicated that the bioactivity of a growth factor can be preserved at room temperature when combined with collagen and the mixture should be kept dried. There was no significant difference between the methods of drying growth factor and collagen mixture.
- bioactivity preservation for various of growth factors Since the bioactivity of growth factor can be preserved by mixing with collagen in a dry state, it is reasonable that the bioactivity of growth factor can be also preserved by combining with other materials such as other extracellular materials.
- NIH3T3 (1.2 ⁇ 10 4 cell/cm 2 ) were seeded to 48-well culture plates and incubated with DMEM-10% FBS until cells attached. This was followed by a medium change to DMEM—1% FBS with indicated concentrations and conditions of growth factors. At day 4, cells were lysed by the freeze-thawing method.
- Hoechst 33258 (Advancing Assay Technologies Bioquest) was prepared with TNE buffer (10 mM Tris-base, 1 mM EDTA, 200 mM NaCl, pH 7.4), and was added to the plates and allowed to stand at room temperature for 10 minutes. A fluorescence reading was taken with excitation at 365 nm and emission at 460 nm (MDI SpectraMax M2e).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Inorganic Chemistry (AREA)
- Environmental Sciences (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
Abstract
Description
- This invention discloses a method for stabilizing bioactivity of a growth factor, and a composition with bioactivity of growth factor preserved and prepared by the method.
- Growth factors comprise a group of proteins responsible for signal transduction inside or between cells, and regulation of cell growth, differentiation, and other functions by binding to specific cell surface receptors.
- There are many types of growth factors, including platelet-derived growth factor (PDGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), transforming growth factor (TGF-α, TGF-β), fibroblast growth factor (FGF), stem cell factor (SCF), insulin-like growth factors (IGF-I, IGF-II), nerve growth factor (NGF), bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), colony stimulating factor (CSF, M-CSF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor, erythropoietin (EPO), endothelial cell monocytes active polypeptide (endothelial-monocyte activating polypeptide), epithelial neutrophil activating peptide, glial derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (GCSF), granulocyte macrophage colony-stimulating factor (GMCSF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), interleukin (IL-1, IL-2, IL-3, etc.), serotonin, tumor necrosis factor (TNF), and von Willebrand factor. Each growth factor has its corresponding receptor(s) and is therefore highly specific.
- The clinical application of growth factors is very extensive, including promoting wound healing, assisting joint repair, regulating periodontal tissue regeneration, facilitating all kinds of tissue regeneration, combining with cell therapies in regenerative medicine, etc. So as related research has also made continuous progress, even for cancer treatment. Due to easy loss of bioactivity of various growth factors, especially the stability and storage of growth factors without freezing and even at room temperature are important for commercial products. Scientists usually designed various kinds of growth factors mutants through recombinant gene engineering techniques or sequence tags [Int. J. Mol. Sci. 2012, 13, 6053-60721 to prolong the bioactivity of growth factors artificially. Nevertheless, adverse effects such as cancer development may affect the normal condition of a human body. Among them, Regranex® Gel is a gel containing recombinant human platelet derived growth factor (rhPDGF). It was approved by US FDA in 1997 for the treatment of foot ulcer wounds complicated by chronic diabetes.
- The rhPDGF in Regranex® Gel is genetically engineered by mutating, deleting, or replacing a naturally occurring PDGF sequence, and then placed in plasmids to produce a recombinant protein, so its bioactivity can be stabilized at room temperature. Although Regranex® Gel is very expensive, inconvenient to use, requiring low-temperature storage, its annual output value is as high as US S270 million, showing that its market demand is quite huge. However, the FDA officially announced that Regranex® Gel may increase the risk of cancer and the risk of death by up to 5 times after more than 10 years of follow-up study. This demonstrates that growth factors containing non-naturally occurring sequences, especially having prolong life-selves may be risk and may not be suitable for clinical treatment.
- However, native growth factors have short half-lives and their bioactivities are rapidly degraded at room temperature, thus limiting the application of native growth factors in clinical treatment.
- Munisso et al. [https://doi.org/10.1155/2019/4016351] also proposed using collagen/gelatin sponges (CGSs) to provide both protection and release of bFGF. Nevertheless, they found that the bioactivity of bFGF in CGSs, not in a dry form, can only be protected for no more than 5 days. In other words, a bioactivity drop of bFGF was significant after 7 days.
- Therefore, a natural method to preserve the bioactivity of growth factors has great demands for the commercial and clinical applications. The current application proposes a natural way of drying the mixture of collagen and growth factors, and the bioactivity of growth factors can be preserved at room temperature for at least 7 days. Furthermore, the bioactivity of growth factors can be preserved with collagen containing extracellular mixtures under a dry state at room temperature. And the bioactivity of growth factors can be resumed in a wet condition.
- In order to solve the above problems, the present invention discloses a method for stabilizing a bioactivity of a growth factor, including: providing a native growth factor; adding a matrix molecule (e.g., a collagen, a collagen derivative, a gelatin, a hyaluronan, or a combination thereof) to the native growth factor; and performing a drying step to obtain a composition with the bioactivity of growth factor preserved. The bioactivity of the growth factor in the composition at room temperature remains stable for at least 7 days.
- After the composition is at room temperature for 7 days or more (e.g., 7 to 20 days, 1-6 months, or 12 months or more), 70%±30% (e.g., 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%) of the bioactivity, as compared to the bioactivity at
day 0, can be preserved. - The term “native growth factor” refers to a growth factor that naturally exists in animal, especially in human, and its amino acid sequence has not been changed by mutations such as insertions, deletions, or replacements. Preferably, the native growth factor is one that exhibits its native activities, e.g., binding to its receptor and mediating downstream events. The native growth factor is selected from, but not limited to: platelet-derived growth factor (PDGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), transforming growth factor (TGF-α, TGF-β), fibroblast growth factor (FGF), stem cell factor (SCF), insulin-like growth factors (IGF-I, IGF-II), nerve growth factor (NGF), bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), colony-stimulating factor (CSF, M-CSF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor, erythropoietin (EPO), endothelial cell monocytes active polypeptide (endothelial-monocyte activating polypeptide), epithelial neutrophil activating peptide, glial derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (GCSF), granulocyte macrophage colony-stimulating factor (GMCSF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), interleukins (IL-1, IL-2, IL-3, etc.), serotonin, tumor necrosis factor (TNF), and von Willebrand factor.
- In one embodiment of the present invention, the drying step is performed by a freeze-drying or lyophilization method.
- In one embodiment of the present invention, the concentration of the matrix molecule is 1 to 100 mg/ml (e.g., 3 to 60 mg/ml, 3 mg/ml, 9, mg/ml, 10 mg/ml, 20 mg/ml, 30 mg/ml, 40 mg/ml, 50 mg/ml, 60 mg/ml, 70 mg/ml, 80 mg/ml, 90 mg/ml, or 100 mg/ml), and the concentration of the growth factor is 1 ng/ml to 1 μg/ml (e.g., 10 to 900 ng/ml, 30 to 900 ng/ml, 100 to 500 ng/ml, 30 ng/ml, 60 ng/ml, 90 ng/ml, 120 ng/ml, 150 ng/ml, 180 ng/ml, 360 ng/ml, or 900 ng/ml). The concentration ratio of the native growth factor to the matrix molecule can be 1×10−9 to 1:1 (e.g., 1×10−3 to 1×10−6:1, or 1.67×10−8 to 3.33×10−4:1).
- In one embodiment of the present invention, the composition of growth factor may be further stored between −80° C. to 37° C.
- The present invention further discloses a growth factor composition in which the bioactivity of the growth factor composition can be preserved for at least seven days at room temperature. The composition is prepared by the preparation method provided by the present invention. The composition includes: a growth factor; and a matrix material. In a preferred embodiment, the concentration ratio of the growth factor to the matrix material is 1×10−3 to 1×10−6:1.
- In one embodiment, the matrix molecule is collagen. In a preferred embodiment, the concentration of the collagen is 3-60 mg/ml.
- In one embodiment of the present invention, the growth factor is selected from the group consisting of, but not limited to: platelet-derived growth factor (PDGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), transforming growth factor (TGF-α, TGF-β), fibroblast growth factor (FGF), stem cell factor (SCF), insulin-like growth factors (IGF-I, IGF-II), nerve growth factor (NGF), bone morphogenetic protein (BMP), connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), colony stimulating factor (CSF, M-CSF), brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor, erythropoietin (EPO), endothelial cell monocytes active polypeptide (endothelial-monocyte activating polypeptide), epithelial neutrophil activating peptide, glial derived neurotrophic factor (GDNF), granulocyte colony-stimulating factor (GCSF), granulocyte macrophage colony-stimulating factor (GMCSF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF), interleukin (IL-1, IL-2, IL-3, etc.), serotonin, tumor necrosis factor (TNF), and von Willebrand factor.
- In one embodiment of the present invention, the growth factor composition can be further stored at −80° C.˜37° C.
-
FIG. 1 shows the bioactivity measurement results of a growth factor PDGF solution atday 0 and stored at −80° C. for 7 months (n=3). -
FIG. 2 shows the bioactivity measurement results of a growth factor PDGF solution subjected to various cycles of freeze-thawing (n=3). -
FIG. 3 shows the bioactivity measurement results of storing a growth factor PDGF solution at various time points at room temperature. -
FIG. 4 shows the bioactivity measurement results of a growth factor PDGF at the indicated concentrations combined with 9 mg/mL of collagen without lyophilization in comparison with a fresh PDGF solution at 6 hours. -
FIG. 5 shows the bioactivity measurement results of a growth factor PDGF at indicated various concentrations combined with 3 mg/mL of collagen and lyophilized in comparison to the bioactivity of the corresponding PDGF solution measured at 6 hours in room temperature. -
FIG. 6 shows the bioactivity measurement results of growth factor PDGF obtained by different preparation methods. Three concentrations of PDGF were lyophilized with collagen or alone without collagen, and together with respective aqueous PDGF solutions, were stored at room temperature for 0, 1, 2, 3, 7 days prior to bioactivity assay. -
FIG. 7 shows the bioactivity measurement results of various growth factors as indicated. The amounts of growth factors and collagen and their preservation condition prior to experiments are as indicated. -
FIG. 8 shows the bioactivity measurement results of various growth factors as indicated. The amounts of growth factors and collagen and their preservation condition prior to experiments are as indicated. - It was unexpectedly discovered that the bioactivity of a native growth factor can be stabilized at room temperature by mixing the growth factor with a matrix molecule and subjecting the mixture to a drying or lyophilization process.
- A matrix molecule can be an extracellular molecule found in the extracellular matrix. Examples are, but are not limited to, collagen, hyaluronan, gelatin, fibronectin, elastin, tenacin, laminin, vitronectin, aggrecan, polypeptides, heparan sulfate, chondroitin, chondroitin sulfate, keratan, keratan sulfate, dermatan sulfate, carrageenan, heparin, chitin, chitosan, alginate, agarose, agar, cellulose, methyl cellulose, carboxyl methyl cellulose, glycogen and derivatives thereof. In addition, the matrix molecule can be fibrin, fibrinogen, thrombin, and polyglutamic acid, a synthetic polymer (e.g., acrylate, polylactic acid, polyglycolic acid, or poly(lactic-co-glycolic acid), silk fibroin, polylysine, polyamino acids.
- Any of the naturally-occurring collagens or their functional variants can be used. At the present time, at least 28 genetically distinct species of collagens have been discovered. Collagen can be easily isolated and purified from collagen-rich tissues such as skin, tendon, ligament, and bone of humans and animals. Methods for isolating and purifying collagen are well known in the art. (See, e.g., U.S. Pat. No. 5,512,291; US Patent Publication 20040138695; Methods in Enzymology, vol. 82, pp. 33-64, 1982; The Preparation of Highly Purified Insoluble Collagen, Oneson, I., et al., Am. Leather Chemists Assoc., Vol. LXV, pp. 440-450, 1970; U.S. Pat. No. 6,090,996). Collagen can also be prepared by recombinant technology, such as those described by Advanced Tissue Sciences (La Jolla, Calif.) or purchased from various venders (e.g., Fibrogen; South San Francisco, Calif.).
- An aqueous solution containing the growth factor and the matrix molecules, and one or more other optional materials can be prepared in a buffered solution having a pH of 2-10 (e.g., a pH of 5 to 8). Low ion solutions such as saline containing 0.135 M NaCl can be used.
- The solution is subjected to a drying process to remove water from the solution. Any suitable drying process known in the art can be used, e.g., freeze-drying, lyophilization, and vacuum drying.
- Once the bioactivity of a growth factor is preserved by combining with a matrix molecule, the addition of other components can still maintain the bioactivity of the growth factor. Preserving the composition in a dry state is also key to maintaining the bioactivity of the growth factor.
- The linear DNA fragments encoding native hPDGF B was obtained from pCMV-SPORT6 (Invitrogen, Grand Island, N.Y. USA) by PCR performed with a sense primer (5′-GGA TTC AGC CTG GGT TCC CTG ACC ATT-3′; SEQ ID NO: 1) and anti-sense primers (5′-GCA GCT GCA CGG CCT GTG ACC TGA-3′; SEQ ID NO: 2) in which the EcoR I sites were introduced. The resulting rhPDGF B cDNA fragment was double digested with EcoR I (TaKaRa, Japan), purified by agarose gel electrophoresis, and cloned into pPICZαA to yield pPICZαA/rhPDGF B. The procedures for small scale preparation of plasmid, digestion with restriction enzymes, ligation, and transformation all followed the standard methods. PCR was carried out using 2.5 U of Taq DNA polymerase (TaKaRa) in a final volume of 50 μL using the following conditions: 95° C. for 10 min, 30 cycles (95° C. for 60 s, 55° C. for 30 s, and 72° C. for 60 s) and a final extension at 72° C. for 7 min.
- Electroporation of X33 and Screening for Recombinant Strains
- The plasmids pPICZαA/rhPDGF B was linearized with Sac I and transformed into yeast Pichia pastoris strain X33 using the electroporation method according to the supplier's instruction. Transformed cells were then plated onto YPDS containing 100 μg/mL zeocin and incubated at 30° C. for at least 3 days. Single colonies were transferred simultaneously onto Minimal Methanol Medium (MM) and Minimal Dextrose Medium (MD) plates to test their methanol utilization phenotype. The MM and MD plates were incubated at 30° C. for 2 days to distinguish between the Muts and Mut+ recombinants. Recombinant strains containing the rhPDGF B gene were screened by colony PCR. Several clones with the Mut+ phenotype that expressed the maximal levels of rhPDGF B was chosen in small-scale expression and stored in YPD containing 15% glycerol for further scale-up cultures.
- Overexpression of rhPDGF B in Yeast
- Selected colonies of zeocin-resistant transformants were inoculated into 5 mL of Yeast Extract-Pepttone-Dextrose (YPD) broth (1% yeast extract, 2% peptone, 2% glucose) containing 100 μg/mL zeocin at 30° C., grown to stationary phase, and used to inoculate 300 mL of Buffered Glycerol-complex Medium (BMGY). After incubation at 30° C. with shaking at 100 rpm, the cells were centrifuged at 3,000×g for 10 min and the pellets resuspended in 1000 mL of Buffered Methanol-Complex Medium (BMMY) to OD600 of 1. The cells were allowed to grow for 72 h at 30° C., and methanol was added every 24 h to a final concentration of 0.5˜1% (v/v) to induce expression of the target protein. After 72 h, cells were removed by centrifugation at 3,000×g for 5 min, and the supernatants were collected. For recombinant protein detection, the supernatants were analyzed by 15% (w/v) SDS-PAGE.
- Secretion of the mature protein was expected to result in protein glycosylation. The construct contained the yeast α-factor promoter, which directs the secretion of rhPDGF B, followed immediately by the sequence for mature rhPDGF B beginning with the glutamate at
amino acid position 1. - Purification of rhPDGF B from Yeast
- Culture supernatants were applied to a phenyl column (GE Healthcare, Piscataway, N.J. USA) pre-equilibrated with buffer (0.01 M sodium phosphate, 1.5 M ammonium sulfate; pH 6). After loading, the column was washed with the same buffer and eluted with a linear gradient of 1.5˜0 M ammonium sulfate in the same buffer. The active fractions (5 mL) were collected using a flow rate of 60 mL/h. After centrifugation at 20,000×g for 30 min at 4° C., each sample was loaded onto a CM-Sepharose (GE Healthcare, Piscataway, N.J. USA) column pre-equilibrated with 0.01 M sodium phosphate buffer, pH 6 using an AKTA explorer 10S system. Fractions containing rhPDGF B were eluted with the same buffer containing 1 M NaCl and collected at a flow rate of 120 mL/h. The eluted solution containing rhPDGF B was concentrated using filter devices with centrifugation at 3,000×g for 60 min at 4° C. and analyzed by 15% SDS-PAGE using Coomassie brilliant blue staining. Western blotting with goat anti-His antibody (1:1000) (Clontech, Mountain View, Calif. USA) was used to detect rhPDGF B with 6-His tag overexpressed from culture supernatant derived from Pichia transformants carry rhPDGF B-6His tag. The amount of purified rhPDGF B was determined by BCA protein analysis using bovine serum albumin (BSA) as a standard.
- The 293-SL/PR cell line was a transformed cell line expressing a PDGF receptor PDGFRβ on the surface of a 293T cell line. The 293-SL/PR cells were seeded at 1×104 cells/cm2 in cultural wells. After cell attachment in DMEM-10% FBS for 20 hours, serum starvation was performed for 16 hours, then different concentrations of PDGF in DMEM-2% FBS were added and cultured at 37° C. in an incubator with 5% CO2. At various time points, cells were lysed with 1× Cell Culture Lysis Buffer (Promega) at room temperature with shaking for 15 min, then were centrifuged at 13,680×g for 10 min at 4° C. Luciferase analysis reagent (100 μL; Promega) was added to 20 μL of the supernatant and bioluminescence was measured in a luminometer (Berthold).
- Referring to
FIG. 1 , the bioactivity of the growth factor PDGF prepared as described above was measured by luciferase assay (day 0), and then stored at −80° C. for seven months. After that, its bioactivity was measured again. The results showed that there were no significant differences in the bioactivity of the growth factor PDGF at different concentrations (0 ng/mL, 18 ng/mL, and 180 ng/mL) atday 0 and seven months later. In addition, the bioactivity of the growth factor PDGF prepared in above was measured under repeated freezing (−80° C.) and thawing (0° C.) mode. As shown inFIG. 2 , repeated freezing-thawing did not reduce bioactivity of the growth factor PDGF. The bioactivity of the growth factor PDGF at different concentrations (18 ng/mL and 180 ng/mL) did not decrease after one, two or three freeze-thaw cycles. Based on the above results, the growth factor PDGF prepared can maintain its bioactivity for at least seven months under storage temperature of −80° C. and had considerable stability in repeated freeze-thaw cycles. - Since the bioactivity of a PDGF solution was very stable under storage temperature of −80° C. and was not susceptible to repeated freeze-thaw cycles, its stability above room temperature was examined. The PDGF prepared as above in Example 1 was dissolved in DMEM and diluted to 180 ng/mL, and incubated at 37° C. for 0, 2, 4, 6, 12, 24, 36, and 48 hours, respectively. The bioactivity of PDGF was measured with a commercially available Human PDGF FlowCytomix Simplex Kit (Invitrogen) and flow cytometry was used to measure bioactivity. The results in
FIG. 3 showed that the PDGF was very unstable at 37° C. - In addition, the PDGF prepared was dissolved in DMEM and diluted to 180 ng/mL, then mixed with 9 mg/mL of collagen. After incubation at 37° C. for 6 hours, the bioactivity was measured, as shown in
FIG. 4 . The results showed that, at the same concentration (180 ng/mL), the growth factor without added collagen had higher bioactivity. Even if 9 mg/mL of collagen was added to the growth factor solutions atconcentrations 900 ng/mL, 1800 ng/mL, and 9000 ng/mL, respectively (see Table 1), the bioactivity did not increase relatively with the growth factor concentration. The results indicated that the release of PDGF was controlled when combined with collagen and demonstrated a lower bioactivity than PDGF solution alone. -
TABLE 1 PDGF concentration Collagen concentration Concentration (ng/ml) (mg/ml) Ratio 180 9 2 * 10−5:1 900 9 1 * 10−4:1 1800 9 2 * 10−4:1 9000 9 1 * 10−3:1 - The native growth factor prepared in Example 1 was combined with collagen and then lyophilized 100 μL of solutions each containing 3 mg/mL of collagen and different concentrations of the growth factor (0, 30, 60, 90, 120, 150, 180, 360 or 900 ng/mL) were prepared. See Table 2. The collagen-growth factor solutions were frozen at −80° C. for 8 hours, and then lyophilized by a freeze dryer. The conditions of the freeze dryer are shown in Table 3.
-
TABLE 2 PDGF Concentration Collagen Concentration Concentration (ng/ml) (mg/ml) Ratio 30 3 1 * 10−5:1 60 3 2 * 10−5:1 90 3 3 * 10−5:1 120 3 4 * 10−4:1 150 3 5 * 10−5:1 180 3 6 * 10−5:1 360 3 1.2 * 10−4:1 900 3 3 * 10−4:1 -
TABLE 3 Temperature Time (° C. ) (min) 16 10 18 10 20 120 22 120 - The results in
FIG. 5 showed that the control group, PDGF solution, exhibited the highest bioactivity at 120 ng/mL (3.4×105 RLU/sec). However, as the growth factor concentration increased, the bioactivity decreased relatively, showing the occurrence of inhibition. In the experimental group, the growth factor had a bioactivity of 3.1×105 RLU/sec at a concentration of 30 ng/mL, and its bioactivity increased relatively as the concentration of the growth factor increased. Besides, the bioactivities of the growth factor at various concentrations lyophilized with collagen were higher than the bioactivities of its corresponding growth factor solution. The results indicate the bioactivity was preserved by lyophilized collagen. - Three forms of growth factor, aqueous solution, lyophilized powder, and lyophilized with collagen, were produced with 0, 60, and 180 ng/mL of PDGF and their bioactivities measured by luciferase assay were compared after incubation at room temperature for 0, 1, 2, 3, and 7 days, and even up to 6 months. The samples were used to treat 293-SL/PR cells for 30 min and their luciferase activity measured. The lyophilized powder group showed baseline luciferase activity, the PDGF solution showed initial luciferase activity before
day 1, and the lyophilized with collagen group showed persistent luciferase activity throughout 6 months of examination (data not all shown). SeeFIG. 6 . The PDGF in the aqueous solution group at 60 ng/mL and 180 ng/mL showed bioactivity atday 0. However, the bioactivity decreased rapidly thereafter. After one day of incubation, the bioactivity of the aqueous solution group was the same as the lyophilized powder group. Compared with the 60 ng/mL PDGF solution group, the bioactivity of the 60 ng/mL lyophilized with collagen combination group was higher, and even slightly increased after 1 day of incubation; the bioactivity was maintained for 6 months (data not shown). The same phenomenon was observed in the 180 ng/mL of PDGF lyophilized with collagen combination group. - The above results showed that the growth factor prepared by mixing with collagen followed by lyophilization exhibited higher and stable bioactivity at room temperature.
- Some growth factors were purchased from commercial resources. In some cases, the native human growth factor gene was purchased from Addgene Headquarters, USA or other resources. The expression vector of the growth factor gene was constructed and screened. It was then overexpressed in a yeast expression system or other suitable expression systems such as CHO cell system and insect system. The expressed growth factor protein was then harvested and purified. Once purified, the growth factor protein was aliquoted and stored at −80° C. to preserve its activity for use.
- The native growth factor prepared as above was frozen at −80° C. and then lyophilized. The lyophilization procedure involved removing ice from the growth factor by sublimation under vacuum condition or under very low pressure. For mixing with collagen, two procedures were taken: (1) Both collagen and growth factor in solutions were mixed initially and followed by a drying step to evaporate water gas under a low atmospheric pressure or a freeze-drying procedure using a lyophilizer; and (2) Collagen was dried initially and immersed in or sprayed with a growth factor solution, followed by a drying step as described above.
- NIH3T3 cells were seeded at 1.2×104 cells/cm2 in a 48-well cultural plate. After cell attachment in DMEM-10% FBS for 24 hours, different concentrations as well as various growth factors in DMEM-1% FBS were cultured at 37° C. in an incubator with 5% CO2. After being cultured for another 3 days, the cells were lysed with sterilized water and DNA was released by freeze-thaw cycles between −80° C. and room temperature. After transferring DNA samples to black fluorescence detection plate, 2 μg/ml of Hoechst 33258 in 1×TNE buffer was added to each well and the fluorescence intensity was detected under excitation at 365 nm and emission at 460 nm. The cell numbers were calculated from cell number standards, which were confirmed by the above DNA detection and cell counting.
- Since bioactivities of growth factors in
FIGS. 7 and 8 were measured by cell proliferation performance as described above, the efficacy of growth factor on cell proliferation corresponded well to its bioactivity throughout the assay period of 3 days. Various growth factors as indicated at either 100 ng/mL (FIG. 7 ) or 500 ng/mL (FIG. 8 ) were mixed with 10 mg/mL or 60 mg/mL of collagen solution or dropped on the indicated dried collagen, and this was followed with water evaporation by a speed vacuum system. There were 6 experimental groups and 6 result bars for each growth factor studied are shown inFIGS. 7 and 8 : (1) freshly prepared growth factor solution, (2) growth factor pre-mixed with 10 mg/mL collagen before lyophilization and stored at −80° C. before use, (3) growth factor pre-mixed with 60 mg/mL collagen before lyophilization and stored at −80° C. before use, (4) growth factor added to dried collagen at 60 mg/mL, lyophilized and stored at −80° C. before use, (5) same as (3) but stored at room temperature for 1 week before use, (6) same as (4) but stored at room temperature for 1 week before use. - The results in
FIGS. 7 and 8 demonstrated that bioactivities of growth factors, aFGF, bFGF, VEGF165, VEGF121, PDGF, and EGF, in aqueous solutions were indeed lower than the bioactivities of corresponding growth factor in combination with collagen. Although the bioactivities varied for different growth factors, higher amount of collagen preserved the bioactivities of growth factors. Compare the second bar with the 3rd to 6th bars in bothFIGS. 7 and 8 . The storage temperature of the dried mixture of growth factor and collagen showed no significant impact on the bioactivities of the growth factors. Compare the 3rd and 4th bars (−80° C. storage) with the corresponding 5th and 6th bars (room temperature storage) in bothFIGS. 7 and 8 . The results indicated that the bioactivity of a growth factor can be preserved at room temperature when combined with collagen and the mixture should be kept dried. There was no significant difference between the methods of drying growth factor and collagen mixture. - It was found that the bioactivities of growth factors after mixing with collagen in a dry state could be preserved for years, and similar bioactivity level was observed for at least 12 months. It was also found that gelatin or collagen derivatives, in replacement of collagen, showed the same effects on bioactivity preservation for various of growth factors. Since the bioactivity of growth factor can be preserved by mixing with collagen in a dry state, it is reasonable that the bioactivity of growth factor can be also preserved by combining with other materials such as other extracellular materials.
- Twenty μl of 15 mg/ml 1560 KDa hyaluronan, 10 mg/ml gelatin or 10 mg/ml albumin containing 100 or 500 ng/ml of growth factor (bFGF and EGF) were prepared respectively and added to 48-well culture plate. The culture plate was frozen for 4 h at −80° C. and lyophilized for 2 h. One plate was stored at 25° C. for 2 days, and the other was stored at −80° C.
- NIH3T3 (1.2×104 cell/cm2) were seeded to 48-well culture plates and incubated with DMEM-10% FBS until cells attached. This was followed by a medium change to DMEM—1% FBS with indicated concentrations and conditions of growth factors. At day 4, cells were lysed by the freeze-thawing method. Hoechst 33258 (Advancing Assay Technologies Bioquest) was prepared with TNE buffer (10 mM Tris-base, 1 mM EDTA, 200 mM NaCl, pH 7.4), and was added to the plates and allowed to stand at room temperature for 10 minutes. A fluorescence reading was taken with excitation at 365 nm and emission at 460 nm (MDI SpectraMax M2e). Although data may vary with the matrix molecule applied, the amount of matrix molecule, kind of growth factor, and the ratio of the growth factor to the matrix molecule in a composition, the results indicated that gelatin, hyaluronan, and albumin can preserve the bioactivity of various growth factors to certain extents.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/418,305 US20220061310A1 (en) | 2018-12-28 | 2019-12-30 | Method for stabilizing bioactivity of growth factor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785888P | 2018-12-28 | 2018-12-28 | |
PCT/US2019/068910 WO2020140112A1 (en) | 2018-12-28 | 2019-12-30 | Method for stabilizing bioactivity of growth factor |
US17/418,305 US20220061310A1 (en) | 2018-12-28 | 2019-12-30 | Method for stabilizing bioactivity of growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220061310A1 true US20220061310A1 (en) | 2022-03-03 |
Family
ID=71126662
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/418,300 Pending US20220062499A1 (en) | 2018-12-28 | 2019-12-30 | Biological scaffold and method for fabricating the same |
US17/418,305 Pending US20220061310A1 (en) | 2018-12-28 | 2019-12-30 | Method for stabilizing bioactivity of growth factor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/418,300 Pending US20220062499A1 (en) | 2018-12-28 | 2019-12-30 | Biological scaffold and method for fabricating the same |
Country Status (8)
Country | Link |
---|---|
US (2) | US20220062499A1 (en) |
EP (1) | EP3902573A4 (en) |
JP (1) | JP2022516123A (en) |
KR (1) | KR20210122242A (en) |
CN (2) | CN113301928B (en) |
AU (1) | AU2019413436A1 (en) |
TW (2) | TWI797407B (en) |
WO (2) | WO2020140112A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114134108A (en) * | 2021-11-30 | 2022-03-04 | 武汉伯韬生物科技有限公司 | Stem cell bioactive composition and preparation method thereof |
CN115105628A (en) * | 2022-07-22 | 2022-09-27 | 广州市暨生元生物科技有限公司 | High-stability recombinant human epidermal growth factor wound repair dressing and preparation method thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ235556A (en) * | 1986-11-05 | 1991-06-25 | Ethicon Inc | Breast milk substitute containing recombinant human egf |
NZ226170A (en) * | 1987-09-18 | 1990-07-26 | Ethicon Inc | Stable freeze-dried pharmaceutical composition containing epidermal growth factor |
US5192743A (en) * | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
AU2007223276B2 (en) * | 2006-03-03 | 2012-12-20 | Organogenesis, Inc. | Oral tissue regeneration and repair |
US20110276147A1 (en) * | 2006-07-20 | 2011-11-10 | Nuvasive, Inc. | Bone Graft Substitutes and Methods Thereof |
CN101234215B (en) * | 2008-03-06 | 2010-12-01 | 西安组织工程工程技术研究中心 | Cell-less composite type artificial skin and preparation thereof |
TWI482781B (en) * | 2009-07-27 | 2015-05-01 | Univ Nat Cheng Kung | Method for preparing porous collagen matrices |
CA2708848C (en) * | 2009-07-27 | 2015-05-05 | National Cheng Kung University | Method for preparing porous collagen matrices |
US8198408B2 (en) * | 2009-07-27 | 2012-06-12 | National Cheng Kung University | Method for preparing porous collagen matrices |
CN102791254A (en) * | 2009-12-22 | 2012-11-21 | 成功大学 | Cell tissue gel containing collagen and hyaluronan |
US9925140B2 (en) * | 2009-12-22 | 2018-03-27 | National Cheng Kung University | Cell tissue gel containing collagen and hyaluronan |
CN101773687B (en) * | 2009-12-31 | 2013-06-05 | 陕西瑞盛生物科技有限公司 | Preparation method of composite soft-tissue patch |
CN104136602B (en) * | 2011-06-23 | 2017-06-09 | 成功大学 | Cell tissue adhesive |
US20120328557A1 (en) * | 2011-06-23 | 2012-12-27 | Excel Med, Llc | Adhesive cell tissue gels |
US10238769B2 (en) * | 2011-10-11 | 2019-03-26 | Fibralign Corporation | Graft for directed vascular and lymphatic regeneration and methods to guide endothelial cell assembly |
EP2900250B1 (en) * | 2012-09-27 | 2018-11-07 | Allergan, Inc. | Biodegradable drug delivery systems for the sustained release of proteins |
EP3185922A4 (en) * | 2014-08-27 | 2018-04-25 | Purdue Research Foundation Office of Technology Commercialization | Collagen-based therapeutic delivery systems |
WO2016049682A1 (en) * | 2014-09-29 | 2016-04-07 | Griffith University | Periodontal tissue grafts |
EP3256070A4 (en) * | 2015-02-10 | 2018-10-17 | Lifenet Health | Biologically functional soft tissue scaffolds and implants |
WO2017011050A2 (en) * | 2015-04-23 | 2017-01-19 | University Of Florida Research Foundation, Inc. | Bilayered devices for enhanced healing |
CN106474547B (en) * | 2015-08-28 | 2019-07-26 | 北京华信佳音医疗科技发展有限责任公司 | A kind of biologic bracket material and preparation method thereof of suitable cell growth |
ES2842501T5 (en) * | 2015-09-21 | 2023-04-13 | Modern Meadow Inc | Fiber Reinforced Fabric Composite Materials |
CN105603133B (en) * | 2015-12-23 | 2018-06-29 | 四川达威科技股份有限公司 | A kind of raw material skin depilating method |
CN107412866A (en) * | 2017-04-07 | 2017-12-01 | 陕西瑞盛生物科技有限公司 | A kind of breast repairs piece and preparation method thereof |
CN107233613B (en) * | 2017-06-07 | 2021-01-26 | 中国海洋大学 | Aquatic organism source cross-linked collagen composite multilayer medical dressing |
-
2019
- 2019-12-30 WO PCT/US2019/068910 patent/WO2020140112A1/en active Application Filing
- 2019-12-30 TW TW108148440A patent/TWI797407B/en active
- 2019-12-30 TW TW108148439A patent/TWI777115B/en active
- 2019-12-30 CN CN201980087040.5A patent/CN113301928B/en active Active
- 2019-12-30 JP JP2021538059A patent/JP2022516123A/en active Pending
- 2019-12-30 US US17/418,300 patent/US20220062499A1/en active Pending
- 2019-12-30 CN CN202310058430.8A patent/CN115869468A/en active Pending
- 2019-12-30 KR KR1020217023732A patent/KR20210122242A/en unknown
- 2019-12-30 WO PCT/US2019/068907 patent/WO2020140111A1/en unknown
- 2019-12-30 EP EP19902921.6A patent/EP3902573A4/en active Pending
- 2019-12-30 AU AU2019413436A patent/AU2019413436A1/en active Pending
- 2019-12-30 US US17/418,305 patent/US20220061310A1/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114134108A (en) * | 2021-11-30 | 2022-03-04 | 武汉伯韬生物科技有限公司 | Stem cell bioactive composition and preparation method thereof |
CN115105628A (en) * | 2022-07-22 | 2022-09-27 | 广州市暨生元生物科技有限公司 | High-stability recombinant human epidermal growth factor wound repair dressing and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2022516123A (en) | 2022-02-24 |
TW202038992A (en) | 2020-11-01 |
CN113301928B (en) | 2022-12-02 |
CN113301928A (en) | 2021-08-24 |
CN115869468A (en) | 2023-03-31 |
WO2020140112A1 (en) | 2020-07-02 |
EP3902573A4 (en) | 2022-08-24 |
TWI797407B (en) | 2023-04-01 |
AU2019413436A1 (en) | 2021-07-01 |
TW202041232A (en) | 2020-11-16 |
KR20210122242A (en) | 2021-10-08 |
TWI777115B (en) | 2022-09-11 |
US20220062499A1 (en) | 2022-03-03 |
EP3902573A1 (en) | 2021-11-03 |
WO2020140111A1 (en) | 2020-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2928513B1 (en) | Peptide-albumin hydrogel properties and its applications | |
Lawrence | Physiology of the acute wound | |
US10493134B2 (en) | Compositions comprising collagen and PRP for tissue regeneration | |
Sheehan et al. | HGF is an autocrine growth factor for skeletal muscle satellite cells in vitro | |
CA2182970C (en) | Lyophilized stem cell factor formulations | |
Aramwit et al. | The effect of sericin with variable amino-acid content from different silk strains on the production of collagen and nitric oxide | |
CN107438666B (en) | Recombinant probiotic | |
US5035887A (en) | Wound healing composition of IL-1 and PDGF or IGF-1 | |
US20220061310A1 (en) | Method for stabilizing bioactivity of growth factor | |
WO2008150101A2 (en) | Chimeric polypeptide including a mussel adheisve protein and extracellular matrix | |
EP1820847B1 (en) | Composition for cell frozen-storage | |
CN108159078A (en) | A kind of Porcine HGF freeze-dried powder, preparation method and application | |
EP0661987B1 (en) | Morphogen-induced liver regeneration | |
KR20200128526A (en) | Umbilical cord mesenchymal stem cell factor frozen powder, manufacturing method and application thereof | |
HU219883B (en) | Heparing-binding proteins, dna encoding them pharmaceutical compositions comprising the proteins and process for their production | |
Ha et al. | Effect of human hepatocyte growth factor on promoting wound healing and preventing scar formation by adenovirus-mediated gene transfer | |
KR20190045080A (en) | Modified egf protein with improved transdermal delivery, cosmetic composition for improvement of skin condition and pharmaceutical composition for preventing or treating skin diseases comprising the same | |
JP2002542824A (en) | Recombinant laminin 5 | |
KR20170136212A (en) | Freeze-dried composition and a method of manufacturing the same, including the stem cell growth factor | |
CN114774357A (en) | Application of polypeptide in preparation of product for promoting skin wound healing | |
JP2023545585A (en) | Combinations of novel bioactive peptides and their uses | |
KR100489731B1 (en) | Pharmaceutical compositions containing domains of fibronectin and βig-h3 for wound healing, cell adhesion, migration and proliferation | |
JPH0920677A (en) | Wound-healing agent | |
CN117285616B (en) | Recombinant humanized I+III type collagen and application thereof | |
KR101903461B1 (en) | Novel peptide for promoting skin condition and regeneration of skin tissue and Uses Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: EXCEL MED, LLC, MISSOURI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUANG, LYNN L.H.;REEL/FRAME:066447/0798 Effective date: 20191227 Owner name: NATIONAL CHENG KUNG UNIVERSITY, TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUANG, LYNN L.H.;REEL/FRAME:066447/0798 Effective date: 20191227 |
|
AS | Assignment |
Owner name: NATIONAL CHENG KUNG UNIVERSITY, TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EXCEL MED, LLC;REEL/FRAME:066532/0877 Effective date: 20240105 |